Contineum Therapeutics Inc - Class A

Research Contineum Therapeutics Inc - Class A (CTNM) on Bullrun: market cap USD 560.80M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCTNM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 560.80M
• Financial periodFY2025
• Net income-USD 59.98M
• Free cash flow-USD 55.54M

Valuation Snapshot

latest market cap is USD 560.80M.

About Contineum Therapeutics Inc - Class A

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Frequently asked questions

What is Contineum Therapeutics Inc - Class A's market cap?

Contineum Therapeutics Inc - Class A's market capitalization is USD 560.80M.

What does Contineum Therapeutics Inc - Class A do?

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.